Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on 'Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35'".